RU2329266C2 - Ингибиторы крузипаина и других цистеинпротеаз - Google Patents
Ингибиторы крузипаина и других цистеинпротеаз Download PDFInfo
- Publication number
- RU2329266C2 RU2329266C2 RU2003125270/04A RU2003125270A RU2329266C2 RU 2329266 C2 RU2329266 C2 RU 2329266C2 RU 2003125270/04 A RU2003125270/04 A RU 2003125270/04A RU 2003125270 A RU2003125270 A RU 2003125270A RU 2329266 C2 RU2329266 C2 RU 2329266C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound according
- group
- phenyl
- disease
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108090000711 cruzipain Proteins 0.000 title abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 11
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 11
- 125000005842 heteroatom Chemical group 0.000 claims abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 7
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 5
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 4
- 206010001935 American trypanosomiasis Diseases 0.000 claims abstract 3
- 208000024699 Chagas disease Diseases 0.000 claims abstract 3
- 241000223109 Trypanosoma cruzi Species 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract 2
- 150000001721 carbon Chemical group 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 229910052740 iodine Inorganic materials 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 30
- 238000011282 treatment Methods 0.000 claims 9
- 102000005927 Cysteine Proteases Human genes 0.000 claims 8
- 108010005843 Cysteine Proteases Proteins 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 4
- 241000222734 Leishmania mexicana Species 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 241000222716 Crithidia Species 0.000 claims 3
- 241000193159 Hathewaya histolytica Species 0.000 claims 3
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 241000233872 Pneumocystis carinii Species 0.000 claims 3
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 201000004792 malaria Diseases 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 201000006938 muscular dystrophy Diseases 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 201000004409 schistosomiasis Diseases 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 241000193403 Clostridium Species 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 229910005965 SO 2 Inorganic materials 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 208000015357 muscle tissue disease Diseases 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 238000012790 confirmation Methods 0.000 abstract 1
- -1 selected from N Inorganic materials 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 0 C*N(*O)C(C(*C1*)I)C1=O Chemical compound C*N(*O)C(C(*C1*)I)C1=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0101179A GB0101179D0 (en) | 2001-01-17 | 2001-01-17 | Biologically active compounds |
| GB0101179.0 | 2001-01-17 | ||
| US27535901P | 2001-03-13 | 2001-03-13 | |
| US60/275,359 | 2001-03-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003125270A RU2003125270A (ru) | 2005-02-20 |
| RU2329266C2 true RU2329266C2 (ru) | 2008-07-20 |
Family
ID=26245571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003125270/04A RU2329266C2 (ru) | 2001-01-17 | 2002-01-17 | Ингибиторы крузипаина и других цистеинпротеаз |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7425562B2 (https=) |
| EP (1) | EP1362052B1 (https=) |
| JP (1) | JP4608183B2 (https=) |
| KR (1) | KR100860067B1 (https=) |
| CN (1) | CN1269822C (https=) |
| AT (1) | ATE356130T1 (https=) |
| AU (1) | AU2002219397B2 (https=) |
| BR (1) | BR0206501A (https=) |
| CA (1) | CA2436462C (https=) |
| CY (1) | CY1106640T1 (https=) |
| DE (1) | DE60218633T2 (https=) |
| DK (1) | DK1362052T3 (https=) |
| ES (1) | ES2281516T3 (https=) |
| IL (2) | IL156774A0 (https=) |
| MX (1) | MXPA03006224A (https=) |
| NO (1) | NO328208B1 (https=) |
| NZ (1) | NZ526913A (https=) |
| PT (1) | PT1362052E (https=) |
| RU (1) | RU2329266C2 (https=) |
| WO (1) | WO2002057270A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
| JP2004523506A (ja) | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
| EP1436255A1 (en) | 2001-09-14 | 2004-07-14 | Aventis Pharmaceuticals, Inc. | Novel compounds and compositions as cathepsin inhibitors |
| YU34604A (sh) | 2001-11-14 | 2006-08-17 | Aventis Pharmaceuticals Inc. | Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže |
| DE60326473D1 (en) * | 2002-07-16 | 2009-04-16 | Amura Therapeutics Ltd | Pyrrolderivate als hemmstoffe von cystein proteasen |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| SE0400022D0 (sv) * | 2004-01-08 | 2004-01-08 | Medivir Ab | New compounds |
| BRPI0506719A (pt) * | 2004-01-08 | 2007-05-02 | Medivir Ab | composto, composição farmacêutica, e, uso de um composto |
| JP2005350417A (ja) * | 2004-06-11 | 2005-12-22 | Dai Ichi Seiyaku Co Ltd | 還元的エーテル化法を用いたピロリジン誘導体の製造法 |
| US7488848B2 (en) * | 2005-03-21 | 2009-02-10 | Virobay, Inc. | Alpha ketoamide compounds as cysteine protease inhibitors |
| GB0513840D0 (en) * | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0513839D0 (en) * | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0614073D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614046D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614037D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614053D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614044D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614052D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| WO2008114054A1 (en) * | 2007-03-19 | 2008-09-25 | Medivir Ab | Protease inhibitors |
| US7893067B2 (en) * | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| GB0804701D0 (en) | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
| GB0804702D0 (en) * | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
| US9409880B2 (en) | 2011-01-20 | 2016-08-09 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of TLR3/dsRNA complex and uses thereof |
| PT2891492T (pt) * | 2012-08-30 | 2022-12-13 | Univ Tokyo | Agente de controlo de endoparasitas |
| CN106279188A (zh) * | 2016-07-21 | 2017-01-04 | 青岛科技大学 | 一种多取代呋喃并[2,3‑b]吡咯衍生物的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1440345A3 (ru) * | 1986-01-17 | 1988-11-23 | Байер Аг (Фирма) | Способ получени производных дигидропиридинлактола |
| RU96114986A (ru) * | 1993-12-15 | 1998-10-20 | Мерк энд Ко, Инк. | Ингибиторы н1v протеазы |
| WO1998050533A1 (en) * | 1997-05-06 | 1998-11-12 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2000069855A2 (en) * | 1999-05-18 | 2000-11-23 | Medivir Uk Limited | Furanone derivatives as inhibitors of cathepsin s |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652574A (en) * | 1970-04-01 | 1972-03-28 | Abbott Lab | Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof |
| RU2137768C1 (ru) * | 1993-12-15 | 1999-09-20 | Мерк энд Ко, Инк. | Ингибиторы hiv протеазы |
| DZ2285A1 (fr) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| EP0923535A4 (en) | 1996-08-28 | 2001-01-10 | Smithkline Beecham Corp | CYSTEINE PROTEASE INHIBITORS |
| EA002100B1 (ru) | 1996-12-23 | 2001-12-24 | Элан Фармасьютикалз, Инк. | ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ |
| MA26618A1 (fr) | 1998-04-09 | 2004-12-20 | Smithkline Beecham Corp | Composes et compositions pharmaceutiques pour le traitement du paludisme |
| CO5150165A1 (es) | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
| JP2004513942A (ja) | 2000-11-17 | 2004-05-13 | メディヴァー ユーケイ リミテッド | システインプロテアーゼインヒビター |
| JP2004523506A (ja) | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
-
2002
- 2002-01-17 US US10/466,384 patent/US7425562B2/en not_active Expired - Fee Related
- 2002-01-17 ES ES02732145T patent/ES2281516T3/es not_active Expired - Lifetime
- 2002-01-17 JP JP2002557947A patent/JP4608183B2/ja not_active Expired - Fee Related
- 2002-01-17 EP EP02732145A patent/EP1362052B1/en not_active Expired - Lifetime
- 2002-01-17 BR BR0206501-0A patent/BR0206501A/pt not_active IP Right Cessation
- 2002-01-17 MX MXPA03006224A patent/MXPA03006224A/es active IP Right Grant
- 2002-01-17 AT AT02732145T patent/ATE356130T1/de active
- 2002-01-17 AU AU2002219397A patent/AU2002219397B2/en not_active Ceased
- 2002-01-17 IL IL15677402A patent/IL156774A0/xx active IP Right Grant
- 2002-01-17 DE DE60218633T patent/DE60218633T2/de not_active Expired - Lifetime
- 2002-01-17 NZ NZ526913A patent/NZ526913A/xx not_active IP Right Cessation
- 2002-01-17 KR KR1020037009524A patent/KR100860067B1/ko not_active Expired - Fee Related
- 2002-01-17 CA CA2436462A patent/CA2436462C/en not_active Expired - Fee Related
- 2002-01-17 WO PCT/GB2002/000184 patent/WO2002057270A1/en not_active Ceased
- 2002-01-17 DK DK02732145T patent/DK1362052T3/da active
- 2002-01-17 RU RU2003125270/04A patent/RU2329266C2/ru not_active IP Right Cessation
- 2002-01-17 CN CNB028038142A patent/CN1269822C/zh not_active Expired - Fee Related
- 2002-01-17 PT PT02732145T patent/PT1362052E/pt unknown
-
2003
- 2003-07-03 IL IL156774A patent/IL156774A/en not_active IP Right Cessation
- 2003-07-16 NO NO20033220A patent/NO328208B1/no not_active IP Right Cessation
-
2007
- 2007-06-04 CY CY20071100742T patent/CY1106640T1/el unknown
-
2008
- 2008-09-15 US US12/211,069 patent/US20090247471A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1440345A3 (ru) * | 1986-01-17 | 1988-11-23 | Байер Аг (Фирма) | Способ получени производных дигидропиридинлактола |
| RU96114986A (ru) * | 1993-12-15 | 1998-10-20 | Мерк энд Ко, Инк. | Ингибиторы н1v протеазы |
| WO1998050533A1 (en) * | 1997-05-06 | 1998-11-12 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2000069855A2 (en) * | 1999-05-18 | 2000-11-23 | Medivir Uk Limited | Furanone derivatives as inhibitors of cathepsin s |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1269822C (zh) | 2006-08-16 |
| JP2004518674A (ja) | 2004-06-24 |
| AU2002219397B2 (en) | 2008-02-14 |
| CA2436462A1 (en) | 2002-07-25 |
| EP1362052A1 (en) | 2003-11-19 |
| HK1060729A1 (en) | 2004-08-20 |
| BR0206501A (pt) | 2004-01-13 |
| CN1486320A (zh) | 2004-03-31 |
| NO20033220L (no) | 2003-09-17 |
| DK1362052T3 (da) | 2007-07-09 |
| WO2002057270A1 (en) | 2002-07-25 |
| US7425562B2 (en) | 2008-09-16 |
| EP1362052B1 (en) | 2007-03-07 |
| CA2436462C (en) | 2011-07-05 |
| IL156774A0 (en) | 2004-02-08 |
| MXPA03006224A (es) | 2004-10-15 |
| US20040138250A1 (en) | 2004-07-15 |
| CY1106640T1 (el) | 2012-01-25 |
| NZ526913A (en) | 2004-12-24 |
| KR100860067B1 (ko) | 2008-09-24 |
| NO328208B1 (no) | 2010-01-11 |
| JP4608183B2 (ja) | 2011-01-05 |
| IL156774A (en) | 2008-08-07 |
| NO20033220D0 (no) | 2003-07-16 |
| DE60218633D1 (de) | 2007-04-19 |
| ES2281516T3 (es) | 2007-10-01 |
| ATE356130T1 (de) | 2007-03-15 |
| DE60218633T2 (de) | 2008-02-21 |
| KR20030075161A (ko) | 2003-09-22 |
| PT1362052E (pt) | 2007-04-30 |
| US20090247471A1 (en) | 2009-10-01 |
| RU2003125270A (ru) | 2005-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2329266C2 (ru) | Ингибиторы крузипаина и других цистеинпротеаз | |
| CA3000661C (en) | Thalidomide analogs and methods of use | |
| JP2004518674A5 (https=) | ||
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
| JP2010539167A (ja) | 免疫機能を調節する組成物および方法 | |
| NO172580C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider | |
| RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
| HUP0100520A1 (hu) | Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok | |
| WO2008008650A1 (en) | Methods for treating cystic kidney diseases | |
| US6562858B2 (en) | Method for treating depression | |
| JPWO2008047880A1 (ja) | 関節リウマチ治療薬 | |
| RU2009105097A (ru) | ТЕТРАГИДРОФУРО(3,2-b)ПИРРОЛ-3-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КАТЕПСИНА К | |
| KR20120083356A (ko) | Ｈｉｖ 감염 치료를 위한 ｎ-히드록시벤즈아미드의 유도체 | |
| DE68917937D1 (de) | Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung. | |
| JP2004520365A5 (https=) | ||
| ATE214269T1 (de) | Oral anzuwendende flüssige arzneilösung | |
| ES2836724T3 (es) | Uso de estiripentol y sus derivados para disminuir la concentración de oxalato urinario en un individuo | |
| Nev et al. | Interleukin-6 Responses in Red Sokoto Bucks Following Orchidectomy, Burdizzo Castration and In-situ Spermatic Cord Ligation | |
| CN1283251C (zh) | 用于预防人类和动物寄生虫感染的驱虫药 | |
| CN1205926C (zh) | 防治新孢子属寄生虫的组合物 | |
| RU2021122029A (ru) | Композиции домперидона и способы лечения депрессии | |
| CN1440280A (zh) | 用于预防人类和动物寄生虫感染的驱虫药ⅱ | |
| ES2726640T3 (es) | Derivados de 2-ciano-3-ciclopropil-3-hidroxi-n-aril-tioacrilamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20131015 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180118 |